Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical Development Co., Ltd and Fosun Adgenvax, will invest RMB 1 billion (USD 144.6 million) to establish an innovative vaccine headquarters and industrialization base in Chengdu Tianfu International Bio-town. The project is expected to be completed within two years.
Project Details
The investment underscores Fosun Pharma’s commitment to expanding its vaccine development and production capabilities. The new facility will serve as a hub for innovative vaccine research, development, and manufacturing, aiming to accelerate the commercialization of vaccine products.
Strategic Significance
Located in Chengdu’s Tianfu International Bio-town, the base will leverage local resources and talent pools to drive innovation in the vaccine sector. Fosun Adgenvax, a key player in vaccine development, will play a pivotal role in the project, further strengthening Fosun Pharma’s position in China’s biotech industry.-Fineline Info & Tech
